Mallinckrodt PLC (NYSE:MNK) – Equities research analysts at Leerink Swann lowered their Q4 2016 EPS estimates for shares of Mallinckrodt PLC in a report issued on Thursday. Leerink Swann analyst J. Gerberry now expects that the firm will post earnings per share of $1.91 for the quarter, down from their prior forecast of $2.00. Leerink Swann currently has a “Outperform” rating and a $92.00 target price on the stock. Leerink Swann also issued estimates for Mallinckrodt PLC’s Q2 2017 earnings at $2.16 EPS, Q3 2017 earnings at $2.02 EPS and Q4 2017 earnings at $2.07 EPS.

A number of other brokerages also recently issued reports on MNK. Wells Fargo & Co. reiterated an “outperform” rating and issued a $83.50 price target (down from $88.50) on shares of Mallinckrodt PLC in a report on Friday, October 21st. Vetr downgraded Mallinckrodt PLC from a “strong-buy” rating to a “buy” rating and set a $72.20 price target on the stock. in a report on Wednesday, July 20th. Zacks Investment Research upgraded Mallinckrodt PLC from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a report on Tuesday, August 30th. Piper Jaffray Cos. lifted their price target on Mallinckrodt PLC from $103.00 to $112.00 and gave the company an “overweight” rating in a report on Wednesday, August 24th. Finally, Barclays PLC reiterated an “overweight” rating and issued a $88.00 price target on shares of Mallinckrodt PLC in a report on Thursday, August 25th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Mallinckrodt PLC presently has an average rating of “Buy” and a consensus price target of $90.52.

Earnings History and Estimates for Mallinckrodt PLC (NYSE:MNK)

Shares of Mallinckrodt PLC (NYSE:MNK) opened at 67.80 on Monday. The stock has a market cap of $7.30 billion, a PE ratio of 12.79 and a beta of 1.62. Mallinckrodt PLC has a 52-week low of $50.90 and a 52-week high of $85.83. The company’s 50-day moving average price is $65.17 and its 200-day moving average price is $66.65.

Several institutional investors have recently added to or reduced their stakes in MNK. Emerald Acquisition Ltd. acquired a new position in shares of Mallinckrodt PLC during the second quarter valued at $35,680,000. Dimensional Fund Advisors LP raised its position in shares of Mallinckrodt PLC by 93.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,187,203 shares of the company’s stock valued at $72,152,000 after buying an additional 573,682 shares in the last quarter. Chartwell Investment Partners LLC acquired a new position in shares of Mallinckrodt PLC during the third quarter valued at $31,922,000. FMR LLC raised its position in shares of Mallinckrodt PLC by 142.8% in the second quarter. FMR LLC now owns 712,469 shares of the company’s stock valued at $43,304,000 after buying an additional 419,057 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Mallinckrodt PLC by 36.5% in the second quarter. Acadian Asset Management LLC now owns 1,299,378 shares of the company’s stock valued at $78,975,000 after buying an additional 347,188 shares in the last quarter. Institutional investors and hedge funds own 94.77% of the company’s stock.

About Mallinckrodt PLC

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

5 Day Chart for NYSE:MNK

Receive News & Stock Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related stocks with our FREE daily email newsletter.